Treating the patient with differentiated thyroid cancer with thyroglobulin-positive iodine-131 diagnostic scan-negative metastases: Including comments on the role of serum thyroglobulin monitoring in tumor surveillance

Seminars in Nuclear Medicine

Volumn 30, Issue 2, 2000, Pages 107-114

  Fatourechi, Vahab ^a,b   Hay, Ian D ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; THYROGLOBULIN;

CELL DIFFERENTIATION; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DRUG EFFECT; DRUG MONITORING; EARLY DIAGNOSIS; HIGH RISK POPULATION; HUMAN; METASTASIS; RECURRENT CANCER; REVIEW; THYROID CANCER;

EID: 0034093097     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/nm.2000.4600     Document Type: Article

References (66)

1. Schlumberger MJ Papillary and follicular thyroid carcinoma N Engl J Med 338 1998 297 306
2. Hay ID Bergstralh EJ Goellner JR Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989 Surgery 114 1993 1050 1057
3. Hay ID Klee GG Thyroid cancer diagnosis and management Clin Lab Med 13 1993 725 734
4. Grebe SK Hay ID Follicular cell-derived thyroid carcinomas Cancer Treat Res 89 1997 91 140
5. Van Herle AJ Vassart G Dumont JE Control of thyroglobulin synthesis and secretion N Engl J Med 301 1979 307 314
6. Hay ID Feld S Baskin HJ AACE clinical practice guidelines for the management of thyroid carcinoma Endocrine Practice 3 1997 60 71
7. Mazzaferri EL Young RL Oertel JE Papillary thyroid carcinoma: the impact of therapy in 576 patients Medicine 56 1977 171 196
8. Mazzaferri EL Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma Thyroid 7 1997 265 271
9. Mazzaferri EL Jhiang SM Differentiated thyroid cancer: long-term impact of initial therapy Trans Am Clin Climatol Assoc 106 1994 151 170
10. Mazzaferri EL Young RL Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients Am J Med 70 1981 511 518
11. Lin JD Kao PF Chao TC The effects of radioactive iodine in thyroid remnant ablation and treatment of well differentiated thyroid carcinoma Br J Radiol 71 1998 307 313
12. Schlumberger M Mancusi F Baudin E 131I therapy for elevated thyroglobulin levels Thyroid 7 1997 273 276
13. Brendel AJ Lambert B Guyot M Low levels of serum thyroglobulin after withdrawal of thyroid suppression therapy in the follow up of differentiated thyroid carcinoma Eur J Nucl Med 16 1990 35 38
14. Pacini F Lippi F Formica N Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels J Nucl Med 28 1987 1888 1891
15. Pineda JD Lee T Ain K Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan J Clin Endocrinol Metab 80 1995 1488 1492
16. Reynolds JC Robbins J The changing role of radioiodine in the management of differentiated thyroid cancer Semin Nucl Med 27 1997 152 164
17. Van Herle AJ Uller RP Matthews NI Radioimmunoassay for measurement of thyroglobulin in human serum J Clin Invest 52 1973 1320 1327
18. Schaadt B Feldt-Rasmussen U Rasmusson B Assessment of the influence of thyroglobulin (Tg) autoantibodies and other interfering factors on the use of serum Tg as tumor marker in differentiated thyroid carcinoma Thyroid 5 1995 165 170
19. Preissner CM Klee GG Krco CJ Nonisotopic “sandwich” immunoassay of thyroglobulin in serum by the biotinstreptavidin technique: evaluation and comparison with an immunoradiometric assay Clin Chem 34 1988 1794 1798
20. Schlumberger M Fragu P Gardet P A new immunoradiometric assay (IRMA) system for thyroglobulin measurement in the follow-up of thyroid cancer patients Eur J Nucl Med 18 1991 153 157
21. Feldt-Rasmussen U Profilis C Colinet E Human thyroglobulin reference material (CRM 457). 1st Part: Assessment of homogeneity, stability and immunoreactivity Ann Biol Clin (Paris) 54 1996 337 342
22. Spencer CA Wang CC Thyroglobulin measurement. Techniques, clinical benefits, and pitfalls. Endocrinol Metab Clin North Am 24 1995 841 863
23. Spencer CA Takeuchi M Kazarosyan M Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma J Clin Endocrinol Metab 83 1998 1121 1127
24. Schlumberger M Baudin E Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma Eur J Endocrinol 138 1998 249 252
25. Tenenbaum F Corone C Schlumberger M Thyroglobulin measurement and postablative iodine-131 total body scan after total thyroidectomy for differentiated thyroid carcinoma in patients with no evidence of disease Eur J Cancer 32A 1996 1262
26. Van Wyngaarden K McDougall IR Is serum thyroglobulin a useful marker for thyroid cancer in patients who have not had ablation of residual thyroid tissue? Thyroid 7 1997 343 346
27. Wartofsky L Sherman SI Gopal J The use of radioactive iodine in patients with papillary and follicular thyroid cancer J Clin Endocrinol Metab 83 1998 4195 4203
28. Grebe SK Hay ID Thyroid cancer nodal metastases: biologic significance and therapeutic considerations Surg Oncol Clin N Am 5 1996 43 63
29. Ozata M Suzuki S Miyamoto T Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer J Clin Endocrinol Metab 79 1994 98 105
30. Powell ME Moskovic EC Harmer CL Surveillance after treatment for well differentiated thyroid cancer: audit for chest radiography Clin Oncol (R Coll Radiol) 6 1994 151 153
31. Schlumberger M Challeton C De Vathaire F Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma J Nucl Med 37 1996 598 605
32. Ladenson PW Braverman LE Mazzaferri EL Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma N Engl J Med 337 1997 888 896
33. Cavalieri RR Nuclear imaging in the management of thyroid carcinoma Thyroid 6 1996 485 492
34. Grigsby PW Baglan K Siegel BA Surveillance of patients to detect recurrent thyroid carcinoma Cancer 85 1999 945 951
35. McDougall IR Whole-body scintigraphy with radioiodine-131: a comprehensive list of false-positives with some examples Clin Nucl Med 20 1995 869 875
36. Venkataraman GM Yatin M Ain KB Cloning of the human sodium-iodide symporter promoter and characterization in a differentiated human thyroid cell line, KAT-50 Thyroid 8 1998 63 69
37. Park HM Park YH Zhou XH Detection of thyroid remnant/metastasis without stunning: an ongoing dilemma Thyroid 7 1997 277 280
38. Sherman SI Tielens ET Sostre S Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma J Clin Endocrinol Metab 78 1994 629 634
39. (abstract) Fatourechi V Hay ID Mullan BP Post-therapy scans in patients with differentiated thyroid cancer: how often do they influence subsequent management? Proceedings of 72nd Annual Meeting 1999 American Thyroid Association Bronx, NY
40. Schlumberger M Challeton C De Vathaire F Treatment of distant metastases of differentiated thyroid carcinoma J Endocrinol Invest 18 1995 170 172
41. Pacini F Cetani F Miccoli P Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine World J Surg 18 1994 600 604
42. Pacini F Elisei R Fugazzola L Post-surgical follow-up of differentiated thyroid cancer J Endocrinol Invest 18 1995 165 166
43. Pachucki J Burmeister LA Evaluation and treatment of persistent thyroglobulinemia in patients with well-differentiated thyroid cancer Eur J Endocrinol 137 1997 254 261
44. Schlumberger M Arcangioli O Piekarski JD Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays J Nucl Med 29 1988 1790 1794
45. Mazzaferri EL Robyn J Postsurgical management of differentiated thyroid carcinoma Otolaryngol Clin North Am 29 1996 637 662
46. Schlumberger M Arcangioli O Piekarski JD Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays J Nucl Med 29 1988 1790 1794
47. Schlumberger M Baudin E Travagli JP Papillary and follicular cancers of the thyroid Presse Med 27 1998 1479 1481
48. Grebe SK Hay ID The role of surgery in the management of differentiated thyroid cancer J Endocrinol Invest 20 1997 32 35
49. Vassilopoulou-Sellin R Schultz PN Haynie TP Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy Cancer 78 1996 493 501
50. Dinneen SF Valimaki MJ Bergstralh EJ Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades J Clin Endocrinol Metab 80 1995 2041 2045
51. Hay ID Papillary thyroid carcinoma Endocrinol Metab Clin North Am 19 1990 545 576
52. Hay ID Klee GG Thyroid cancer diagnosis and management Clin Lab Med 13 1993 725 734
53. Clark OH Hoelting T Management of patients with differentiated thyroid cancer who have positive serum thyroglobulin levels and negative radioiodine scans Thyroid 4 1994 501 505
54. McDougall IR 131I treatment of 131I negative whole body scan, and positive thyroglobulin in differentiated thyroid carcinoma: what is being treated? Thyroid 7 1997 69 72
55. Mazzaferri EL Treating high thyroglobulin with radioiodine: a magic bullet or a shot in the dark? J Clin Endocrinol Metab 80 1995 1485 1487
56. Ronga G Fiorentino A Paserio E Can iodine-131 whole-body scan be replaced by thyroglobulin measurement in the post-surgical follow-up of differentiated thyroid carcinoma? J Nucl Med 31 1990 1766 1771
57. Rudavsky AZ Freeman LM Treatment of scan-negative, thyroglobulin-positive metastatic thyroid cancer using radioiodine 131I and recombinant human thyroid stimulating hormone J Clin Endocrinol Metab 82 1997 11 14
58. Lubin E Mechlis-Frish S Zatz S Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma J Nucl Med 35 1994 257 262
59. (abstract) Fatourechi V Hay ID Mullan BP How often do post-therapy scans in thyroglobulin-positive diagnostic scannegative patients with differentiated thyroid cancer show meaningful uptake in areas of known metastases Proceedings of 72nd Annual Meeting of the American Thyroid Association Bronx, NY 1999 16
60. Schlumberger M Challeton C De Vathaire F Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma J Nucl Med 37 1996 598 605
61. Harder W Lind P Molnar M Thallium-201 uptake with negative iodine-131 scintigraphy and serum thyroglobulin in metastatic oxyphilic papillary thyroid carcinoma J Nucl Med 39 1998 236 238
62. Mallin WH Elgazzar AH Maxon HR Imaging modalities in the follow-up of non-iodine avid thyroid carcinoma Am J Otolaryngol 15 1994 417 422
63. Grunwald F Menzel C Bender H Comparison of 18FDG-PET with 131 iodine and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer Thyroid 7 1997 327 335
64. Dietlein M Scheidhauer K Voth E Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer Eur J Nucl Med 24 1997 1342 1348
65. Dietlein M Scheidhauer K Voth E Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm? Nuklearmedizin 37 1998 12 17
66. Baudin E Schlumberger M Lumbroso J Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan J Clin Endocrinol Metab 81 1996 2541 2544